
Plus Therapeutics, Inc.
Plus Therapeutics, Inc. (PSTV) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PSTV · as of Jun 9, 2026
Key Statistics
Explore Plus Therapeutics, Inc. Data
pstv stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 75.0%
The PSTV analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $25.00, representing +352.08% upside from the current price of $5.53.
Competitors & Peers
pstv competitorsStock Performance
Full HistoryAbout Plus Therapeutics, Inc.
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and indiv…
what is plus therapeutics, inc. · pstv stock overview · plus therapeutics, inc. company profile · who is plus therapeutics, inc. ceo · pstv NASDAQ · plus therapeutics, inc. headquarters · plus therapeutics, inc. business segments
About Stock Overview & Key Data
Plus Therapeutics, Inc. (PSTV) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 11, 2001. As of the latest trading session, PSTV stock price is $5.53, with a market capitalization of $13.4M. The stock has returned -36.51% over the past 12 months and -56.83% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Plus Therapeutics, Inc. stock is Buy, with an average 12-month price target of $25.00. In fiscal year 2025, Plus Therapeutics, Inc. reported revenue of $5.2M and net income of -$22.4M. For detailed data — including Plus Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Plus Therapeutics, Inc. (PSTV) stock price is $5.53. The stock is traded on NASDAQ under the ticker symbol PSTV. The 52-week range is $2.90 – $23.50.